

SUPPLEMENTARY MATERIAL

Landscape of Combination Therapy Trials in Breast Cancer Brain Metastasis

Jawad Fares, Deepak Kanojia, Aida Rashidi, Ilya Ulasov, and Maciej S. Lesniak

TABLE OF CONTENTS

Supplementary Tables


- Supplementary Table 1: Distribution of trials that use two classes of chemotherapeutic agents for breast cancer brain metastasis (n=37)
- Supplementary Table 2: Distribution of trials that use three classes of chemotherapeutic agents for breast cancer brain metastasis (n=7)

Supplementary Figures


- Supplementary Figure 1: Selection of combination trials
- Supplementary Figure 2: Distribution of combination trials and patients across phases
- Supplementary Figure 3: Percent of combination trial publication

Supplementary Table 1: Distribution of trials that use two classes of chemotherapeutic agents for breast cancer brain metastasis (n=37)									
	HER-dimerization inhibitor	Tyrosine kinase inhibitor	PD-1/PD-L1 inhibitor	VEGF-A inhibitor	PARP inhibitor	Alpha interferon	Alkylating agent	PI3K inhibitor	DNA polymerase inhibitor
HER-dimerization inhibitor	3	3	1	-	-	-	-	-	-
CDK inhibitor	1	-	-	-	-	-	-	-	-
PI3K inhibitor	2	-	-	-	-	-	-	-	-
Thymidylate synthase inhibitor	1	6	-	1	-	1	-	1	-
Microtubule inhibitor	1	3	-	1	-	-	1	-	-
Alkylating agent	-	1	-	1	1	-	-	-	-
Topoisomerase inhibitor	1	1	-	-	1	-	1	-	-
mTOR inhibitor	-	1	-	-	-	-	-	-	-
Aromatase inhibitor	-	1	-	-	-	-	-	-	-
WT1 peptide vaccine	-	-	1	-	-	-	-	-	-
Dihydrofolate reductase inhibitor	-	-	-	-	-	-	-	-	1

Supplementary Table 2: Distribution of trials that use three classes of chemotherapeutic agents for breast cancer brain metastasis (n=7)			
Trial Number	Combination of 3 Agents		
NCT03199885	HER-dimerization inhibitor	PD-1/PD-L1 inhibitor	Microtubule inhibitor
NCT02185352 NCT01281696	VEGF-A inhibitor	Topoisomerase inhibitor	Alkylating agent
NCT01783756	Tyrosine kinase inhibitor	Thymidylate synthase inhibitor	mTOR inhibitor
NCT01305941	mTOR inhibitor	HER-dimerization inhibitor	Microtubule inhibitor
NCT01025349	VEGF-A inhibitor	Microtubule inhibitor	Alkylating agent
NCT00397501	Dihydrofolate reductase inhibitor	HER-dimerization inhibitor	Alkylating agent




Supplementary Figure 1: Selection of combination trials



Supplementary Figure 2: Distribution of combination trials and patients across phases

Cumulative Incidence of Trial Publication



Supplementary Figure 3: Percent of combination trial publication